Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Media
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsShorts
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

The Era of Immunotherapy for Advanced Head & Neck Cancer Squamous Cell Carcinoma

EP. 1: Biology of Head and Neck Squamous Cell Cancer (HNSCC)

December 22nd 2016

EP. 2: Risk Stratification for HNSCC

December 22nd 2016

EP. 3: Multimodality Treatment for HNSCC

December 22nd 2016

EP. 4: Historic Perspective on Systemic Therapy for Advanced HNSCC

December 22nd 2016

EP. 5: Historic Perspective on Recurrent HNSCC

December 22nd 2016

EP. 6: Mechanisms of Immunotherapy in HNSCC

December 22nd 2016

EP. 7: Immunotherapy for Virally Induced vs High-Mutation Burden HNSCC

December 22nd 2016

EP. 8: The Approval of Pembrolizumab for Recurrent HNSCC

December 22nd 2016

EP. 9: Immunotherapy for Recurrent HNSCC

December 22nd 2016

EP. 10: Nivolumab: A New Standard-of-Care

December 22nd 2016

EP. 11: Nivolumab-Related Efficacy and Toxicity in HNSCC Patients

December 22nd 2016

EP. 12: Patient Selection for Nivolumab in HNSCC

December 22nd 2016

EP. 13: Ongoing Research of Immunotherapy in HNSCC

December 22nd 2016

EP. 14: Emerging PD-L1 Inhibitors for HNSCC

December 22nd 2016
Advertisement
Advertisement

Trending on OncLive

1

ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC

2

The OncFive: Top Oncology Articles for the Week of 5/31

3

CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026

4

From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving

5

Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us